Document Detail

Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan.
MedLine Citation:
PMID:  20586973     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The development of long-acting, injectable atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The study was designed to assess whether a risperidone long-acting injection (RLAI) is associated with reduced relapses and service utilization in the real world. METHODS: The Psychiatric Inpatients Medical Claims dataset was used for the analysis. It is a longitudinal dataset that includes the National Health Insurance claims of service uses by a cohort of mentally ill patients. The inclusion criteria for this analysis were patients who: 1) had available information for at least 12 months after the first dose of RLAI; 2) had a primary diagnosis of schizophrenia; and 3) were regularly treated with RLAI for at least 1 year. Patients who accumulatively received at least 75-mg RLAI per 3-month period were considered to be undergoing regular treatment. Wilcoxon signed rank tests were performed to compare differences in numbers of acute admissions, hospital days, emergency room visits, and relapses between the pre- and post-RLAI periods in this 1-year mirror-image study. RESULTS: In total, 108 patients were eligible for analysis. Significant reductions in the total annual numbers of acute hospital admissions by 55% (80 vs. 36, P = 0.0003), hospital days by 48% (4106 vs. 2126, P = 0.0021), and relapses by 54% (115 vs. 53, P = 0.0005) were observed. A reduction of emergency room visits was also observed, but did not reach statistical significance (55 vs. 25, P = 0.1255). CONCLUSIONS: This 1-year mirror-image analysis with claims-based data demonstrated that RLAI treatment was associated with reductions in relapses and hospital service utilization.
Kuan-Pin Su; Hui-Chih Chang; Shih-Jen Tsai; Feng-Chang Yen; Chao-Hsiun Tang
Related Documents :
24143063 - Extension educators' perceptions of community readiness, knowledge of prevention scienc...
12642883 - Metropolitan-nonmetropolitan differences in amount and type of mental health treatment.
17060983 - Houston biosecurity: building a national model.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research     Volume:  12 Suppl 3     ISSN:  1524-4733     ISO Abbreviation:  Value Health     Publication Date:    2009 Nov-Dec
Date Detail:
Created Date:  2010-06-30     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883818     Medline TA:  Value Health     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S118-21     Citation Subset:  IM    
Department of Psychiatry, Mind-Body Interface Research Centre, and Graduate Institute of Neural and Cognitive Sciences, China Medical University & Hospital, Taichung, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / administration & dosage,  economics*
Cost-Benefit Analysis
Databases, Factual
Follow-Up Studies
Injections, Intramuscular
Length of Stay
Middle Aged
National Health Programs / economics*
Outcome Assessment (Health Care) / economics
Recurrence / prevention & control
Risperidone / administration & dosage*,  economics*
Schizophrenia / drug therapy,  economics*
Young Adult
Reg. No./Substance:
0/Antipsychotic Agents; 106266-06-2/Risperidone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community resid...
Next Document:  Evidence-based decision-making on medical technologies in China, Japan, and Singapore.